In the TRISCEND II trial, a total of 400 patients with severe symptomatic tricuspid regurgitation were randomized in a 2:1 ratio to undergo either transcatheter tricuspid valve replacement with medical therapy (valve-replacement group) or medical therapy alone (control group). A total of 267 patients were assigned to the valve replacement group and 133 to the control group. At one-year, tricuspid valve replacement and medical therapy were superior to medical therapy alone, with a win ratio of 2.02 (95 percent confidence interval [CI], 1.56 to 2.62; P
You are here:
Transcatheter Valve Replacement in Severe Tricuspid Regurgitation
Submitted by: Mateo Marin-Cuartas
Source: New England Journal of Medicine
Keywords:
Author(s): Rebecca T. Hahn, Raj Makkar, Vinod H. Thourani, Moody Makar, Rahul P. Sharma, Christiane Haeffele, Charles J. Davidson, Akhil Narang, Brian O’Neill, James Lee, Pradeep Yadav, Firas Zahr, Scott Chadderdon, Mackram Eleid, Sorin Pislaru, Robert Smith, Molly Szerlip, Brian Whisenant, Nishant K. Sekaran, Santiago Garcia, Terri Stewart-Dehner, Holger Thiele, Robert Kipperman, Konstantinos Koulogiannis, D. Scott Lim, Dale Fowler, Samir Kapadia, Serge C. Harb, Paul A. Grayburn, Anna Sannino, Michael J. Mack, Martin B. Leon, Philipp Lurz, Susheel K. Kodali
